We observed that prophylactic treatment using CBs from B16 and B16-ISAV generates a delay in tumor growth in B16 melanoma model, but only the treatment with B16-ISAV CBs showed an increase in systemic CD8+ and CD4+ lymphocytes which are associated with an antitumor response. The gene discussed is CD4; the disease is neoplasm.